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A total of 3173 dyslipidemic patients treated with LLA and
managed by general practitioners were randomly selected from
a French GPs computerized database. History of CHD and
number of CRF (age, family history of premature CHD,
smoking, hypertension, HDL-C < 0.9mmol/L, diabetes) were
documented. Percent of patients above AFSSAPS TIL and NCEP
goal was deﬁned for each level of CHD risk. RESULTS: Twenty-
one percent of patients had a history of CHD. Using AFSSAPS
guidelines the distribution of primary prevention patients
according to the number of CRFs (1, 2, 3, >3) was 1.6, 25.5,
31.7, and 20.1%, respectively. Almost 40% of CHD patients
remained above TIL and the percentages of primary prevention
patients above TIL varied from 3.9% for patients with 1 CRF
to 46.5% for patients with > 3 CRFs (p < 0.001). Using NCEP
guidelines, percentage of patients not at goal in the different
CHD risk categories were signiﬁcantly higher and 74.3% of
CHD patients were not at LDL-C treatment goal. CONCLU-
SION: Seventy-three percent of patients prescribed LLA were at
high CHD risk. Increasing with CHD risk level, large numbers
of patients were above TIL and LDL-C treatment goal. More
effective interventions are needed in lipid lowering therapy. *
AFSSAPS: French Drug Agency.
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META-ANALYSIS
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OBJECTIVES: To examine the relationship between Interna-
tional Normalized Ratio (INR) and outcomes (major bleeding
events and strokes) in atrial ﬁbrillation (AF) patients on antico-
agulation with warfarin. METHODS: A systematic review and
meta-analysis of studies published in English between January 1,
1985 and October 30, 2002 was performed. MEDLINE
(PubMed), Current Contents, and relevant reference lists were
searched. Studies enrolling patients with nonvalvular AF on war-
farin anticoagulation were eligible for inclusion if they reported
stroke and/or major bleeding events in relation to INR, or time
spent in therapeutic range. The risk of bleeds in overanticoagu-
lated patients (INR > 3) and the risk of strokes in underantico-
agulated patients (INR < 2) was assessed. RESULTS: Twenty-one
studies (6,248 patients) met all inclusion criteria. Of the 21
studies, target conventional INR of 2 to 3 was used in 9. An INR
< 2, compared with an INR > 2, was associated with an odds
ratio (OR) for ischemic events of 5.07 (95% conﬁdence interval
(CI) = 2.92, 8.80). An INR > 3, compared with an INR < 3, was
associated with an OR for bleeding events of 3.21 (95% CI =
1.24, 8.28). On average, in the four studies with a target INR
range of 2 to 3, AF patients on warfarin spent 61% of time
within, 13% of time above and 26% below the therapeutic
range. CONCLUSION: Available evidence indicates that in
patients with non-valvular AF, the risk of ischemic stroke with
insufﬁcient warfarin anticoagulation (INR < 2), and the risk of
bleeding events with overanticoagulation (INR > 3) is signiﬁ-
cantly higher relative to AF patients maintained within the rec-
ommended INR of 2 to 3. However, the data are sparse,
heterogeneous, and mostly based on clinical trials. More studies
evaluating clinical outcomes in relation to INR are needed, espe-
cially in a real-world setting.
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LIPID MANAGEMENT AND FACTORS AFFECTING GOAL
ATTAINMENT IN LATIN AMERICA
Meaney E1,Armaganijan D2, Ruiz A3, Ramos A4, Alemao E5,
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OBJECTIVE: Evaluate treatment of hyperlipidemia in Latin
America and determine factors associated with NCEP-III LDL-
C goal attainment in Coronary Heart Disease (CHD)/CHD risk
equivalent (< = 100mg/dl) and non-CHD patients with 2+ risk
factor (< = 130mg/dl). METHODS: Retrospective observational
study at 40 randomly selected specialists and 20 general prac-
tices (GP) centers in Mexico, Brazil and Colombia. Physicians
randomly selected adult (age > = 18) patients prescribed lipid
lowering drug (LLD) for minimum 12 weeks. Date of ﬁrst LLD
was the index date; follow-up cholesterol measures and LLD pre-
scribed were evaluated for minimum 3 months after index date.
RESULTS: Three-hundred sixty patients were studied, 25% from
GP and 75% from specialist centers; 45% had CHD/CHD equiv-
alent, and 35% had 2+ risk factors. Mean age was 57yrs (SD
12) and 53% were male. Median LDL-C reduction required to
attain NCEP-III goal at baseline was 48% for CHD and 23%
for non-CHD patients. There was no signiﬁcant difference in
LDL-C reduction required at baseline among the three countries.
Initial LLD for CHD group were 27% low dose statins (sim-
vastatin 10mg or equipotent), 36% medium dose statins 
(simvastatin 20mg or equipotent) and 18% high dose statins
(simvastatin 40mg or equipotent). Proportion of physicians 
prescribing high dose statins was higher (p < 0.05) in Brazil
(26%) than Mexico (16%) and Colombia (15%). Overall 45%
patients treated with statins alone attained LDL-C goals; 
only 28% of CHD group. After controlling for age, gender,
country, initial LLD, titration and comorbidities, patients with
baseline LDL-C > = 190mg/dl (OR = 0.47; 95% CI 0.30–0.74),
hypertension (OR = 0.58; 95% CI 0.37–0.92) and CHD (OR =
0.38; 95% CI 0.24–0.60) were least likely to achieve LDL-C
goal. CONCLUSION: Hyperlipidemic patients in some Lati-
namerican countries are generally treated with statins alone;
majority (55%) of patients failed to reach recommended NCEP-
III LDL-C goals.
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THE IMPACT OF ADEQUATE MONITORING OF LIPID LEVELS
IN PATIENTS HAVING ELECTIVE PERCUTANEOUS
CORONARY INTERVENTIONS IN A LOCAL PUBLIC HOSPITAL
IN HONG KONG
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OBJECTIVES: Clinical trials demonstrated that low-density
lipoprotein (LDL) lowering therapy reduces mortality and mor-
bidity in coronary heart disease patients. Therefore, it is impor-
tant to ensure patient adhering to their LDL-lowering therapies.
In July 2001, an intensive treatment protocol was introduced at
the United Christian Hospital (UCH) in Hong Kong. The
purpose of this study is to describe the impact of the protocol
on the lipid levels in patients having elective percutaneous coro-
nary interventions (PCI). METHODS: Case notes were reviewed
retrospectively. The study cohort consisted of patients who were
above 18 years old requiring ﬁrst elective PCI from 1 July 2000
to 30 June 2002. Patients with a history of previous PCI or 
coronary artery bypass surgery were excluded. The intensive
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monitoring started from 1 July 2001. The primary outcome mea-
surement was the LDL levels. The secondary outcome measure-
ment was the percentage of goal attainment. Lipid control was
deﬁned as adequate if the LDL level was < or = 2.6mmol/L. The
LDL levels were measured at baseline, 1, 3, 6, and 12 months.
RESULTS: A total of 617 patients were recruited. There were
383 patients in the intensive monitoring group and 283 patients
in the control group. In the control group, a less intensive mon-
itoring was adopted. Less than 20% of control group patients
had a regular 3-monthly LDL-levels monitoring. Over 60% of
patients in the intensive monitoring group and 10% of the
control group patients reached target LDL-levels by week 4.
Over 90% of the intensive monitoring group patients maintained
at target LDL levels in a following 6-month period. CONCLU-
SION: This study shows that intensive monitoring of LDL-levels
in hyperlipidaemic patients receiving PCI have a higher goal
attainment rate that remains high within 6-month period. This
study paves way for a prospective, randomized-control trial to
conﬁrm the results in the future.
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LONGITUDINAL DESIGN
Al-Zakwani I1, Bullano MF1,Willey VJ1, Cziraky MJ1, Hoffman L2
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OBJECTIVES: To evaluate lipid level changes, NCEP-ATPIII
LDL-C goal attainment and time to goal in a managed care
setting. METHODS: Patients were included if they began ator-
vastatin, ﬂuvastatin, pravastatin, or simvastatin therapy between
July 1, 1999 and June 30, 2001, and had no dyslipidemic therapy
in the previous 6 months, continuous health plan enrollment, 6
months pre-index and 12 months post-index, and post-index
lipid measurements. Goal attainment status was assessed at each
LDL-C lab result utilizing NCEP-ATPIII guidelines. Descriptive
statistics, generalized estimating equations (GEE), and Cox 
proportional hazard with multiple-failure data were employed
for analysis. Model covariates included age, gender, coronary
artery disease, diabetes mellitus, hypertension, duration of statin
therapy, medication possession ratio (MPR), and baseline lipid
proﬁle. RESULTS: A total of 16,979 patients were identiﬁed for
this study (ﬂuvastatin = 1251; pravastatin = 2302; simvastatin =
5603; atorvastatin = 7823). The mean overall age of the cohort
was 62 ± 13 years, 49% were male, and 58% of patients were
deﬁned as secondary prevention by NCEP-ATPIII risk criteria.
The overall mean duration of therapy (persistence) was 16 ± 9
months and adherence to therapy (MPR) was 79%. The
mean/median doses were as follows: atorvastatin = 14mg/10mg,
ﬂuvastatin = 35mg/40mg, pravastatin = 28mg/20mg and sim-
vastatin = 24mg/20mg. Changes in lipid levels for atorvastatin,
ﬂuvastatin, pravastatin, and simvastatin were as follows: total
cholesterol (-21%, -15%, -16%, -20%), LDL-C (-28%, 
-21%, -23%, -28%), HDL-C (0.1%, 1.0%, 1.0%, 1.5%), 
and triglycerides (-8%, -1%, -3%, -5%), respectively. The
probabilities of achieving LDL-C goal and median times to 
goal were: atorvastatin (0.51, 236 days); ﬂuvastatin (0.30, 379
days); pravastatin (0.35, 377 days); simvastatin (0.47, 246 
days). CONCLUSIONS: Patients who were prescribed atorvas-
tatin had signiﬁcantly greater improvements in total cholesterol
and triglycerides and attained LDL-C goal signiﬁcantly more
often evaluating each lab result independently. Changes in 
LDL-C and HDL-C were similar between atorvastatin and 
simvastatin.
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OBJECTIVE: Angiotension II receptor antagonists (ARB)
provide a new therapeutic option for hypertensive patients. This
analysis examines patient utilization patterns subsequent to ini-
tiation on an ARBs. METHODS: This study uses a retrospective
cohort design with a six-month baseline period and a twelve-
month evaluation period. New users of ARBs were identiﬁed in
AdvancePCS¢ pharmacy claims database. Studied patients were
continuously eligible for pharmacy beneﬁts, 20 to 80 years of
age, and initiated therapy on losartan, valsartan, ibersartan, can-
desartan, telmisartan, losartan HCT, valsartan HCT, candesar-
tan HCT, or telmisartan HCT between November 1, 2001 and
April 30, 2002. RESULTS: A total of 167,083 patients initiated
ARB therapy during the enrollment window, 72% on ARB
monotherapy and 28% on combination therapy. Monotherapy
patients (p < 0.05) were more likely to discontinue than combi-
nation therapy patients. No other signiﬁcant differences in 
discontinuation rates were identiﬁed. Patients who initiated with
monotherapy were equally likely to add a diuretic as a second
therapy regardless of ARB. Patients who initiated on telmisartan
were less likely (p < 0.05) than patients who initiated on losar-
tan (OR = 0.67), valsartan (OR = 0.81), ibersartan (OR = 0.82),
or candesartan (OR = 0.82) to receive triple anti-hypertensive
therapy. Similarly, patients who initiated on valsartan (OR =
1.23) or losartan monotherapy (OR = 1.14) were more likely
than other monotherapy patients (p < 0.05) to titrate upwards.
Combination patients who initiated on losartan HCT or valsar-
tan HCT were more likely to add another anti-hypertensive drug
than were patients who initiated on either candesartan HCT (OR
= 0.69, p < 0.05) or telmisartan HCT (OR = 0.82, p < 0.05).
Those who initiated telmisartan HCT were least likely to
increase the initial dose (p < 0.05). CONCLUSIONS: Differences
in patient utilization patterns were identiﬁed based on initial
choice of ARB. These ﬁndings may result from differential clin-
ical efﬁcacy, patient health history, or managed care inﬂuence on
drug choice.
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RECENT EVIDENCE SURROUNDING THE EFFICACY OF
PROTECTED CAROTID ANGIOPLASTY WITH STENTS
Burton K
University of Toronto,Toronto, ON, Canada
OBJECTIVES: Carotid artery stenosis is an important risk factor
for, and is also believed to cause as much as 20% all strokes.
Several surgical therapies are available including carotid
endarterectomy (CEA) and carotid angioplasty with stenting
(CAS). Although there appear to be beneﬁts to adopting wide-
spread use of CAS, numerous parties have expressed concern
about its safety. A number of large protected CAS (PCAS) trials
are underway, however, it will be 3 to 5 years until these results
are released. In the interim, PCAS continues to be employed.
Since numerous PCAS studies were recently published, the aim
of this systematic review was to answer the question: based on
the most recent evidence, what is the efﬁcacy of protected carotid
angioplasty with stenting (PCAS)? METHODS: Electronic,
manual and bibliographic searches of Medline, PreMedline,
Healthstar/OVID, EMBase, PubMed were conducted.
RESULTS: Over 400 articles were identiﬁed, of which 18 studies
met the inclusion criteria. The technical complication rate of
